Find, prioritize, and evaluate external innovation across global scientific, clinical, regulatory, financial, patent, deal and conference signals, all in one evidence-grounded intelligence workflow.
OneZyme.ai has been a highly valuable platform for business development, R&D, and competitive intelligence workflows, particularly in helping synthesize complex biotech and pharma landscapes with a high degree of accuracy and practical relevance. Beyond the strength of the platform itself, the One Zyme team has been exceptionally responsive, thoughtful, and open to feedback, making it clear that they are building with real-world BD, strategy, and executive decision-making needs in mind. I have found the tool to be a strong resource for accelerating insight generation while maintaining the level of rigor required in biotech and pharma.
Therapeutic area, indication, target, mechanism, modality, stage, geography, ownership status, TPP criteria, and deal preferences, parsed from one natural-language brief.
Scientific literature, clinical trials, conference data, patents, regulatory filings, SEC/CDE/FDA sources, company websites, venture/grant financing, licensing, M&A, and uploaded materials.
Sponsors, assets, targets, mechanisms, indications, investigators, trials, regulatory events, publications, patents, financings, licensing, M&A, and corporate structures, collapsed into canonical records.
Scientific rationale, clinical stage, differentiation, financing, partnerability, competitive intensity, China relevance, and customer-specific priorities, scored and sorted.
Concise analysis with clickable references, supporting rationale, open questions, and recommended next steps with every claim cited.
Opportunity briefs, watchlists, monitoring alerts, conference target lists, diligence memos, board-ready summaries, and CRM-ready outputs.
One Zyme assembles fragmented public, private, structured, and unstructured data into a continuously updated, source-cited intelligence layer.
China is now one of the most important sources of emerging biopharma innovation. One Zyme brings China visibility directly into search and evaluation, surfacing assets, competitors, and signals traditional databases miss.
Spot programs before they reach Western awareness.
Track IND filings and active China trials in real time.
Catch priority review and breakthrough designations.
Map CNIPA families and cross-border filings.
Resolve subsidiaries, JVs, and related parties.
Assess licensing readiness and existing relationships.
One Zyme connects trial, patent, financing, discovery, preclinical and even hidden company structure signals across China's biopharma landscape so search and evaluation teams can identify emerging assets before the market catches up.
One Zyme turns weeks of fragmented research into a single integrated BD workflow.
Global scan across scientific, clinical, regulatory, financial, patent, deal, and conference sources.
Strategic-fit ranking of the most relevant assets and companies for your TPP.
Mechanism, data, and translational rationale, every claim source-grounded.
Full view of competing assets, trials, IP, financing, plus in-depth deal-comp analysis with precedents, structures, and valuation context.
Enterprise-ready presentation assembled from the cited analysis above.
Drop in an asset. One Zyme drafts your team's TPP against it, every field grounded in cited evidence, every comparison made against the assets and competitors that matter.
Indication, MoA, efficacy bar, safety, mfg, comps, differentiation, strategy, your structure, every time.
From the FDA label to ChiCTR registrations to conference posters, fields populate with sourced answers.
Spin up TPPs for every comparable asset, and rank them against your team's strategic criteria.
Get a strategic briefing tailored to your therapeutic areas, TPP criteria, competitor set, China visibility needs, and external innovation priorities.
